Cell cycle checkpoint in cancer: a therapeutically targetable double-edged sword

Major currently used anticancer therapeutics either directly damage DNA or target and upset basic cell division mechanisms like DNA replication and chromosome segregation. These insults elicit activation of cell cycle checkpoints, safeguard mechanisms that cells implement to correctly complete cell cycle phases, repair damage or eventually commit suicide in case damage is unrepairable. Although cancer cells appear to be advantageously defective in some aspects of checkpoint physiology, recent acquisitions on the biochemical mechanisms of the various checkpoints are offering new therapeutic approaches against cancer. Indeed, chemical manipulation of these mechanisms is providing new therapeutic strategies and tools to increase the killing efficacy of major cancer therapeutics as well as to directly promote cancer cell death. In this review we summarize developing concepts on how targeting cell cycle checkpoints may provide substantial improvement to cancer therapy.

[1]  H. Piwnica-Worms,et al.  Inactivation of the p34cdc2-cyclin B complex by the human WEE1 tyrosine kinase. , 1992, Science.

[2]  C. Turck,et al.  Inhibition of CDK2 activity in vivo by an associated 20K regulatory subunit , 1993, Nature.

[3]  T. Lagerweij,et al.  WEE1 Kinase Inhibition Enhances the Radiation Response of Diffuse Intrinsic Pontine Gliomas , 2012, Molecular Cancer Therapeutics.

[4]  C. Koh,et al.  Mitosis-targeted anti-cancer therapies: where they stand , 2012, Cell Death and Disease.

[5]  Y Taya,et al.  Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. , 1998, Science.

[6]  M. Meuth,et al.  Treatment with the Chk1 inhibitor Gö6976 enhances cisplatin cytotoxicity in SCLC cells. , 2011, International journal of oncology.

[7]  S. Elledge,et al.  The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases , 1993, Cell.

[8]  Domenico Grieco,et al.  The spindle checkpoint requires cyclin-dependent kinase activity. , 2003, Genes & development.

[9]  L. Cascione,et al.  Combined inhibition of Chk1 and Wee1 as a new therapeutic strategy for mantle cell lymphoma , 2014, Oncotarget.

[10]  Tianhong Li,et al.  A phase II study of cell cycle inhibitor UCN-01 in patients with metastatic melanoma: a California Cancer Consortium trial , 2010, Investigational New Drugs.

[11]  Nicola J. Curtin,et al.  DNA repair dysregulation from cancer driver to therapeutic target , 2012, Nature Reviews Cancer.

[12]  A. Venook,et al.  Phase I dose-escalation trial of checkpoint kinase 1 inhibitor MK-8776 as monotherapy and in combination with gemcitabine in patients with advanced solid tumors. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  H. Hirai,et al.  MK-1775, a small molecule Wee1 inhibitor, enhances anti-tumor efficacy of various DNA-damaging agents, including 5-fluorouracil , 2010, Cancer biology & therapy.

[14]  G. Inman,et al.  DNA damage in human B cells can induce apoptosis, proceeding from G1/S when p53 is transactivation competent and G2/M when it is transactivation defective. , 1995, The EMBO journal.

[15]  P. Nurse,et al.  Chk1 is a wee1 kinase in the G2 DNA damage checkpoint inhibiting cdc2 by Y15 phosphorylation , 1997, The EMBO journal.

[16]  P. Renhowe,et al.  Inhibitors of kinesin motor proteins--research and clinical progress. , 2005, Current opinion in drug discovery & development.

[17]  P. Clarke,et al.  Phosphorylation of caspase-9 by CDK1/cyclin B1 protects mitotic cells against apoptosis. , 2007, Molecular cell.

[18]  Tsuyoshi Arai,et al.  Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents , 2009, Molecular Cancer Therapeutics.

[19]  Yoichi Taya,et al.  DNA Damage-Induced Phosphorylation of p53 Alleviates Inhibition by MDM2 , 1997, Cell.

[20]  Xin Lu,et al.  Live or let die: the cell's response to p53 , 2002, Nature Reviews Cancer.

[21]  M. McDevitt,et al.  Phase I and Pharmacologic Trial of Cytosine Arabinoside with the Selective Checkpoint 1 Inhibitor Sch 900776 in Refractory Acute Leukemias , 2012, Clinical Cancer Research.

[22]  A. Maitra,et al.  MK-1775, a Potent Wee1 Inhibitor, Synergizes with Gemcitabine to Achieve Tumor Regressions, Selectively in p53-Deficient Pancreatic Cancer Xenografts , 2011, Clinical Cancer Research.

[23]  Erich A. Nigg,et al.  Cell division: Mitotic kinases as regulators of cell division and its checkpoints , 2001, Nature Reviews Molecular Cell Biology.

[24]  V. Costanzo,et al.  Mechanisms of replication fork protection: a safeguard for genome stability , 2012, Critical reviews in biochemistry and molecular biology.

[25]  A. Eastman,et al.  A novel indolocarbazole, ICP-1, abrogates DNA damage-induced cell cycle arrest and enhances cytotoxicity: similarities and differences to the cell cycle checkpoint abrogator UCN-01. , 2002, Molecular cancer therapeutics.

[26]  L. del Vecchio,et al.  The Fcp1-Wee1-Cdk1 axis affects spindle assembly checkpoint robustness and sensitivity to antimicrotubule cancer drugs , 2015, Cell Death and Differentiation.

[27]  P. Clarke,et al.  Phosphorylation of Mcl‐1 by CDK1–cyclin B1 initiates its Cdc20‐dependent destruction during mitotic arrest , 2010, The EMBO journal.

[28]  A. Eastman,et al.  Will targeting Chk1 have a role in the future of cancer therapy? , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  T. Hunter,et al.  Cyclins and cancer II: Cyclin D and CDK inhibitors come of age , 1994, Cell.

[30]  P. O'Connor,et al.  Breaching the DNA damage checkpoint via PF-00477736, a novel small-molecule inhibitor of checkpoint kinase 1 , 2008, Molecular Cancer Therapeutics.

[31]  Xiao-yu Wu,et al.  Inhibition of Aurora B by CCT137690 sensitizes colorectal cells to radiotherapy , 2014, Journal of Experimental & Clinical Cancer Research.

[32]  D. Haas-Kogan,et al.  WEE1 Kinase As a Target for Cancer Therapy. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  D. Grieco,et al.  The end of mitosis from a phosphatase perspective , 2013, Cell cycle.

[34]  G. Chan,et al.  Checkpoint inhibition of the APC/C in HeLa cells is mediated by a complex of BUBR1, BUB3, CDC20, and MAD2 , 2001, The Journal of cell biology.

[35]  L. Karnitz,et al.  Pharmacological Abrogation of S-Phase Checkpoint Enhances the Anti-Tumor Activity of Gemcitabine In Vivo , 2007, Cell cycle.

[36]  T. Buchholz,et al.  MK-1775, a Novel Wee1 Kinase Inhibitor, Radiosensitizes p53-Defective Human Tumor Cells , 2011, Clinical Cancer Research.

[37]  S. Robinson,et al.  CCT244747 Is a Novel Potent and Selective CHK1 Inhibitor with Oral Efficacy Alone and in Combination with Genotoxic Anticancer Drugs , 2012, Clinical Cancer Research.

[38]  J. Doroshow,et al.  Phase I Study of Single-Agent AZD1775 (MK-1775), a Wee1 Kinase Inhibitor, in Patients With Refractory Solid Tumors. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  J. Trent,et al.  WAF1, a potential mediator of p53 tumor suppression , 1993, Cell.

[40]  Y. Shiloh,et al.  The ATM protein kinase: regulating the cellular response to genotoxic stress, and more. , 2013, Nature reviews. Molecular cell biology.

[41]  N. Mailand,et al.  Rapid destruction of human Cdc25A in response to DNA damage. , 2000, Science.

[42]  D. Grieco,et al.  New insights on oxidative stress in cancer. , 2009, Current opinion in drug discovery & development.

[43]  J. Doroshow,et al.  The Cyclin-Dependent Kinase Inhibitor UCN-01 Plus Cisplatin in Advanced Solid Tumors: A California Cancer Consortium Phase I Pharmacokinetic and Molecular Correlative Trial , 2005, Clinical Cancer Research.

[44]  K. Cimprich Probing ATR Activation with Model DNA Templates , 2007, Cell cycle.

[45]  Yair Benita,et al.  Preclinical Evaluation of the WEE1 Inhibitor MK-1775 as Single-Agent Anticancer Therapy , 2013, Molecular Cancer Therapeutics.

[46]  Yasushi Okuno,et al.  Hypersensitivity reactions to anticancer agents: Data mining of the public version of the FDA adverse event reporting system, AERS , 2011, Journal of experimental & clinical cancer research : CR.

[47]  A. Fattaey,et al.  Human Myt1 Is a Cell Cycle-regulated Kinase That Inhibits Cdc2 but Not Cdk2 Activity* , 1997, The Journal of Biological Chemistry.

[48]  M. Ernstoff,et al.  Modulation of Cell Cycle Progression in Human Tumors: A Pharmacokinetic and Tumor Molecular Pharmacodynamic Study of Cisplatin Plus the Chk1 Inhibitor UCN-01 (NSC 638850) , 2006, Clinical Cancer Research.

[49]  D. Grieco,et al.  Fcp1-dependent dephosphorylation is required for M-phase-promoting factor inactivation at mitosis exit , 2012, Nature Communications.

[50]  J. Bartek,et al.  DNA damage checkpoints: from initiation to recovery or adaptation. , 2007, Current opinion in cell biology.

[51]  S. Elledge,et al.  Linkage of ATM to cell cycle regulation by the Chk2 protein kinase. , 1998, Science.

[52]  D. Grieco,et al.  Fcp1 phosphatase controls Greatwall kinase to promote PP2A-B55 activation and mitotic progression , 2015, eLife.

[53]  K. Cimprich,et al.  ATR: an essential regulator of genome integrity , 2008, Nature Reviews Molecular Cell Biology.

[54]  J. Bartek,et al.  The DNA-damage response in human biology and disease , 2009, Nature.

[55]  L. Galluzzi,et al.  Mitotic catastrophe: a mechanism for avoiding genomic instability , 2011, Nature Reviews Molecular Cell Biology.

[56]  H. B. El-Nassan,et al.  Advances in the discovery of kinesin spindle protein (Eg5) inhibitors as antitumor agents. , 2013, European journal of medicinal chemistry.

[57]  Helder Maiato,et al.  Stuck in division or passing through: what happens when cells cannot satisfy the spindle assembly checkpoint. , 2004, Developmental cell.

[58]  Stephen S. Taylor,et al.  How do anti-mitotic drugs kill cancer cells? , 2009, Journal of Cell Science.

[59]  M. Bui,et al.  MK1775, a Selective Wee1 Inhibitor, Shows Single-Agent Antitumor Activity against Sarcoma Cells , 2011, Molecular Cancer Therapeutics.

[60]  A. Eastman,et al.  Preclinical Development of the Novel Chk1 Inhibitor SCH900776 in Combination with DNA-Damaging Agents and Antimetabolites , 2011, Molecular Cancer Therapeutics.

[61]  N. Xu,et al.  CDK1 switches mitotic arrest to apoptosis by phosphorylating Bcl‐2/Bax family proteins during treatment with microtubule interfering agents , 2014, Cell biology international.

[62]  G. Peng,et al.  Long non-coding RNA ANRIL (CDKN2B-AS) is induced by the ATM-E2F1 signaling pathway. , 2013, Cellular signalling.

[63]  N. Turner,et al.  Tumour selective targeting of cell cycle kinases for cancer treatment. , 2013, Current opinion in pharmacology.

[64]  A. Ashworth,et al.  Forced mitotic entry of S-phase cells as a therapeutic strategy induced by inhibition of WEE1. , 2012, Cancer discovery.

[65]  T. Chambers,et al.  Identification of a mitotic death signature in cancer cell lines. , 2014, Cancer letters.

[66]  N. Curtin,et al.  Targeting the S and G2 checkpoint to treat cancer. , 2012, Drug discovery today.

[67]  S. Patzke,et al.  Cyclin-Dependent Kinase Suppression by WEE1 Kinase Protects the Genome through Control of Replication Initiation and Nucleotide Consumption , 2012, Molecular and Cellular Biology.

[68]  N. Mailand,et al.  The ATM–Chk2–Cdc25A checkpoint pathway guards against radioresistant DNA synthesis , 2001, Nature.

[69]  S. Chandna,et al.  Peptidyl prolyl isomerase, Pin1 is a potential target for enhancing the therapeutic efficacy of etoposide. , 2011, Current cancer drug targets.

[70]  Conly L. Rieder,et al.  Mitotic Checkpoint Slippage in Humans Occurs via Cyclin B Destruction in the Presence of an Active Checkpoint , 2006, Current Biology.

[71]  Paraskevi Giannakakou,et al.  Targeting microtubules for cancer chemotherapy. , 2005, Current medicinal chemistry. Anti-cancer agents.

[72]  J. Sarkaria,et al.  Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines , 2011, British Journal of Cancer.

[73]  Y Taya,et al.  Enhanced phosphorylation of p53 by ATM in response to DNA damage. , 1998, Science.

[74]  J. Bartek,et al.  Inhibition of Chk1 by CEP-3891 Accelerates Mitotic Nuclear Fragmentation in Response to Ionizing Radiation , 2004, Cancer Research.

[75]  David A. Smith,et al.  Phase II evaluation of LY2603618, a first-generation CHK1 inhibitor, in combination with pemetrexed in patients with advanced or metastatic non-small cell lung cancer , 2016, Investigational New Drugs.

[76]  Xiaoxiao Hu,et al.  miRNA response to DNA damage. , 2011, Trends in biochemical sciences.

[77]  W. Mellado,et al.  Taxol: Mechanisms of Action and Resistance a , 1986, Journal of the National Cancer Institute. Monographs.

[78]  Mark T. W. Ebbert,et al.  A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer , 2012, Breast Cancer Research and Treatment.

[79]  E. Sausville,et al.  Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors , 2014, Cancer Chemotherapy and Pharmacology.

[80]  C. Sherr Cancer Cell Cycles , 1996, Science.

[81]  E. Salmon,et al.  The spindle-assembly checkpoint in space and time , 2007, Nature Reviews Molecular Cell Biology.

[82]  Jonathan Maybaum,et al.  Gemcitabine sensitization by checkpoint kinase 1 inhibition correlates with inhibition of a Rad51 DNA damage response in pancreatic cancer cells , 2009, Molecular Cancer Therapeutics.

[83]  Yuan Zhang,et al.  The expression of PLK-1 in cervical carcinoma: a possible target for enhancing chemosensitivity , 2009, Journal of experimental & clinical cancer research : CR.

[84]  S. Elledge,et al.  Conservation of the Chk1 checkpoint pathway in mammals: linkage of DNA damage to Cdk regulation through Cdc25. , 1997, Science.

[85]  A. Eastman,et al.  Enhancement of cisplatin-induced cytotoxicity by 7-hydroxystaurosporine (UCN-01), a new G2-checkpoint inhibitor. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[86]  R. Medema,et al.  Shared and separate functions of polo-like kinases and aurora kinases in cancer , 2010, Nature Reviews Cancer.

[87]  S. Haggarty,et al.  Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen. , 1999, Science.

[88]  A. Gunasekera,et al.  Chk1 Mediates S and G2 Arrests through Cdc25A Degradation in Response to DNA-damaging Agents* , 2003, Journal of Biological Chemistry.

[89]  Hua-mei Tang,et al.  Elevated kinesin family member 26B is a prognostic biomarker and a potential therapeutic target for colorectal cancer , 2015, Journal of Experimental & Clinical Cancer Research.

[90]  Stephen S. Taylor,et al.  Mitosis and apoptosis: how is the balance set? , 2013, Current opinion in cell biology.

[91]  Jiri Bartek,et al.  Cell-cycle checkpoints and cancer , 2004, Nature.